Valley Grande Manor administered olanzapine to Resident #1 twice daily under a physician's order that listed "Alzheimer's disease, unspecified" as the medical justification. Federal inspectors found no appropriate indication for the medication during a January 30 complaint investigation.
The resident had severely impaired cognition with a score of 3 on the Brief Interview for Mental Status assessment. His medical record showed diagnoses of Alzheimer's disease and vascular dementia, conditions that destroy memory and thinking skills through progressive brain damage.
Staff at the facility understood the dangers. During interviews with federal inspectors, both the pharmacist and assistant director of nursing stated that antipsychotic medications given to residents with Alzheimer's disease could cause death.
"Alzheimer's disease was not an appropriate diagnosis for an antipsychotic medication," the facility pharmacist told inspectors during a phone interview on January 30. "Antipsychotic for a resident with Alzheimer's disease could cause death."
The assistant director of nursing echoed this concern in a separate interview the same day. She confirmed that antipsychotic medications could cause death in residents with Alzheimer's or dementia, which was why they were not recommended for these conditions.
Yet the facility continued administering the medication. Records show Resident #1 received olanzapine oral tablets from January 6 through January 5, according to electronic medication administration records reviewed by inspectors. The physician's order, dated January 1, specified no end date for the treatment.
The director of nursing defended the practice during her interview with inspectors at 7:50 p.m. on January 30. While looking at her computer screen, she read Resident #1's olanzapine order aloud to inspectors.
She stated that using Alzheimer's disease as an indication was acceptable because "Resident #1 came with that order from the hospital."
The facility had established protocols that should have prevented this situation. Valley Grande Manor's own policy on antipsychotic medication use, revised in December 2016, specified that these drugs "may be considered for residents with dementia but only after medical, physical, functional, psychological, emotional psychiatric, social and environmental causes of behavioral symptoms have been identified and addressed."
The inspection found no evidence that staff had conducted this comprehensive evaluation before continuing the antipsychotic treatment.
Resident #1's care plan, dated January 1, acknowledged he was using antipsychotic medications related to Alzheimer's disease. The plan called for monitoring side effects and effectiveness every shift, along with documenting and reporting any adverse reactions to the antipsychotic medications.
The facility had also implemented side effect monitoring for olanzapine every shift starting December 31, 2025, and behavior monitoring for the same medication beginning the same date.
Olanzapine, marketed as Zyprexa, belongs to a class of medications called atypical antipsychotics. The drug carries significant risks for elderly patients with dementia, including increased mortality rates. Federal regulations require nursing homes to ensure residents are free from chemical restraints that are not medically necessary.
The resident's admission record from January 29 showed he was admitted to Valley Grande Manor from a hospital setting. His MDS assessment from January 6 classified him as being on a high-risk drug due to the antipsychotic medication.
Inspectors determined that the facility failed to ensure Resident #1 was free from chemical restraints not required to treat his medical symptoms. The violation put him at risk of receiving unnecessary psychotropic medications that could cause serious harm.
The inspection classified the violation as causing minimal harm or potential for actual harm, affecting few residents. However, the consequences for Resident #1 remained significant given the acknowledged death risk associated with his treatment.
Federal regulations mandate that nursing homes prevent the use of unnecessary psychotropic medications and avoid drugs that may restrain a resident's ability to function. The inspection found Valley Grande Manor violated these requirements by continuing antipsychotic treatment without adequate medical justification.
The facility's own staff recognized the dangers. The pharmacist's statement that antipsychotics could cause death in Alzheimer's patients directly contradicted the continued administration of olanzapine to Resident #1 for this exact condition.
The assistant director of nursing's acknowledgment that such medications were not recommended for residents with Alzheimer's or dementia further highlighted the gap between facility knowledge and practice.
Despite these concerns from clinical staff, the director of nursing's justification relied solely on the fact that the resident arrived with the hospital order. This approach failed to meet the facility's own policy requirements for comprehensive evaluation before antipsychotic use in dementia patients.
The inspection revealed a troubling disconnect between stated policies, staff knowledge, and actual practice. While Valley Grande Manor had written protocols requiring thorough assessment before antipsychotic use in dementia, and while key staff understood the mortality risks, the facility continued administering the medication based solely on a hospital transfer order.
Resident #1 continued receiving twice-daily doses of a medication that facility staff acknowledged could kill him, with no documented reassessment of medical necessity or exploration of alternative approaches to his care.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Valley Grande Manor from 2026-01-30 including all violations, facility responses, and corrective action plans.